1-(2,4,5-三甲基苯基)-2-硫脲 | 117174-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2,4,5-三甲基苯基)-2-硫脲
• 英文名称: 1-(2,4,5-trimethylphenyl)thiourea
• 英文别名: (2,4,5-trimethyl-phenyl)-thiourea；(2,4,5-Trimethyl-phenyl)-thioharnstoff；2,4,5-trimethylphenyl thiourea；1-(2,4,5-Trimethylphenyl)-2-thiourea；(2,4,5-trimethylphenyl)thiourea
• CAS: 117174-87-5
• 化学式: C₁₀H₁₄N₂S
• mdl: MFCD00060438
• 分子量: 194.301
• InChiKey: QVCQPIJMAAOGKX-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162°C
• 沸点：
  307.8±52.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2930909090
• 危险类别：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-(2,4,5-三甲基苯基)-2-硫脲 在 三乙胺 作用下， 以 甲醇 、 叔丁醇 为溶剂， 反应 29.0h， 生成 N-(2,4,5-Trimethyl-phenyl)-morpholine-4-carboxamidine; hydriodide
  参考文献：
  名称：

  A Versatile Synthesis of NovelN,N,N″-Trisubstituted Guanidines

  摘要：

  N,N,N″-三取代胍（大部分是N″-芳基-N-氮杂环烷羧基亚胺）通常以良好的产率通过以下步骤制备：将单取代硫脲与甲基碘在甲醇或丙酮中进行S-甲基化反应，然后将所得的甲基氨基甲亚胺硫醇氢碘酸盐与二级胺在沸腾的叔丁醇或丙酮腈中反应。

  DOI：

  10.1055/s-1988-27606
• 作为产物：
  描述：

  2,4,5-三甲基苯胺 在 乙醇 、 氨 、 水 作用下， 生成 1-(2,4,5-三甲基苯基)-2-硫脲
  参考文献：
  名称：

  Dyson; George, Journal of the Chemical Society, 1924, vol. 125, p. 1704

  摘要：

  DOI：

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas
  作者：C. R. Rasmussen、F. J. Villani, Jr.、L. E. Weaner、B. E. Reynolds、A. R. Hood、L. R. Hecker、S. O. Nortey、A. Hanslin、M. J. Costanzo、E. T. Powell、A. J. Molinari

  DOI：10.1055/s-1988-27605

  日期：——

  An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N′-benzoylthioureas with 5% aqueous sodium hydroxide. Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g., 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.

  制备芳基硫脲的改进方法包括将苯甲酰异硫氰酸酯与苯胺在丙酮中反应，然后用5%氢氧化钠水溶液对生成的N-芳基-N'-苯甲酰硫脲进行去苯甲酰化。双环烷基硫脲和N-(芳烷基)硫脲（例如9H-9-芴基硫脲）可直接由相应的异硫氰酸酯与氨反应制备。
• Discovery of aryl aminothiazole γ-secretase modulators with novel effects on amyloid β-peptide production
  作者：Sanjay Bhattarai、Lei Liu、Michael S. Wolfe

  DOI：10.1016/j.bmcl.2021.128446

  日期：2021.12

  A series of analogs based on a prototype aryl aminothiazole γ-secretase modulator (GSM) were synthesized and tested for their effects on the profile of 37-to-42-residue amyloid β-peptides (Aβ), generated through processive proteolysis of precursor protein substrate by γ-secretase. Certain substitutions on the terminal aryl D ring resulted in an altered profile of Aβ production compared to that seen

  合成了一系列基于原型芳基氨基噻唑 γ-分泌酶调节剂 (GSM) 的类似物，并测试了它们对通过前体蛋白的持续蛋白水解产生的 37 至 42 残基淀粉样蛋白 β 肽 (Aβ) 的影响γ-分泌酶的底物。与母体分子相比，末端芳基 D 环上的某些取代导致 Aβ 产生的变化。微小的结构变化导致 Aβ37 和 Aβ38 产量的浓度依赖性增加，而它们的前体 Aβ40 和 Aβ42 分别没有平行减少。因此，新化合物显然也刺激了 Aβ 肽的羧肽酶修剪≥ 43 个残基，为 γ-分泌酶进行性蛋白水解的机理研究提供了新的化学工具。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。